...A. Although we had a relatively mature product portfolio, we had -- one of the higher OpEx to sales ratios in our -- among our peer group, and we needed to address that. B. So as I look at where we are in the third quarter, we actually had LEQEMBI was the first anti-amyloid antibody to receive traditional approval for early Alzheimer's disease. C. As expected, we received schedule IV listing from the DEA, and we also had QALSODY approved for treating a genetic cause of ALS. D. As I noted, we closed the acquisition of Reata Pharmaceuticals, and that gives us a whole new growth opportunity. E. Biogen has been very successful with the launch of SPINRAZA, and we think we can do the same with SKYCLARYS. F. So we do think those cost savings will add meaningfully to our earnings per share as we look forward. G. We all know that the Cleveland Clinic is one of the most widely respected medical centers anywhere in the world, and they recently announced that they had just infused their first patient...
